Allogeneic bone marrow or stem cell transplantation is a curative therapeutic option for chronic myelogenous leukemia. In order to decrease the toxicity of the procedure, the dosage of total body irradiation was reduced from 12 to 8 Gy and subsequently the dose of cyclophosphamide from 120 to 80 mg/kg. The purine analogue fludarabine, ATG, cyclosporine A and a short course of methotrexate were given for immune suppression. So far, 35 elderly CML patients with sibling and unrelated donors have been transplanted. Transplantrelated mortality at day þ 100 was 11%. After engraftment, all patients achieved a complete cytogenetic remission. Relapse occurred in 14% of the patients. The risk of relapse was significantly higher in those patients transplanted in second chronic or accelerated phase (P ¼ 0.048). After a median follow-up of 30 months (range 12-62), 63% of the patients are alive. Those patients transplanted within the first year from diagnosis had an overall survival of 79% (P ¼ 0.049), emphasizing the benefit of early transplantation. Stepwise reduction of conditioning intensity resulted in stable engraftment, low relapse rates and encouraging overall survival in this highrisk patient group. Allogeneic bone marrow transplantation (BMT) has been used successfully for the treatment of chronic myelogenous leukemia (CML). The classical conditioning regimen has been 12 Gy total body irradiation (TBI) or high-dose busulfan plus cyclophosphamide (CY) and optionally ATG.
intensity conditioning; allogeneic transplantation Allogeneic bone marrow transplantation (BMT) has been used successfully for the treatment of chronic myelogenous leukemia (CML). The classical conditioning regimen has been 12 Gy total body irradiation (TBI) or high-dose busulfan plus cyclophosphamide (CY) and optionally ATG. 1, 2 Long-term remissions can be achieved in 75-80% of the patients depending on their individual pretransplant risk score. 3, 4 Due to a considerable rate of transplant-related mortality (TRM), the procedure has been limited to young patients in good medical condition. The main reasons for this high TRM are therapy related toxicity and graft-versus-host disease (GvHD), occurring more frequently with increasing age and poor medical status. 5 As the median age of the CML patients is beyond the fifth decade, 6 only a minority of the patients were able to benefit from this curative therapy option. In order to decrease toxicity, reducedintensity conditioning (RIC) was introduced. This idea was driven by the finding that the curative potential of allogeneic BMT is not solely based on the intensity of conditioning but also on the immunologic graft-versusleukemia (GvL) effect. The existence of the GvL effect first became evident as CML patients who had suffered a relapse after allogeneic BMT could be successfully transferred into molecular remission via donor lymphocyte infusion (DLI). 7, 8 In addition, RIC seems to be associated with less severe GvHD. 9, 10 Recently, a variety of RIC protocols have been published. The regimens and substances applied are often as heterogeneous as the underlying hematological malignancies. So far, there are limited data on patients in the early-stage CML transplanted with RIC. Initial studies reported a considerable amount of graft rejection and relapse. 9, [11] [12] [13] [14] [15] In order to decrease toxicity without compromising engraftment, relapse and cure rates, we decided to reduce the intensity of the conditioning regimen stepwise. The preparative regimen consisted of 8 Gy TBI, 4 Â 30 mg/m 2 fludarabine, 120 (80) mg/kg CY and 40 mg/kg ATG. So far, 35 CML patients 45 years and older with sibling as well as unrelated donors have been transplanted.
Patients and methods

Patients
A total of 35 RIC patients have been included in this analysis. Patients were eligible for analysis if they were 45 years and older and had BCR-ABL-positive CML in chronic or accelerated phase before undergoing allogeneic transplantation. HLA-identical sibling or a matched unrelated donor was accepted. All patients had given their written consent for the procedure. The conditioning regimen was accepted and integrated into the German CML study for elderly patients. The patient characteristics are shown in Table 1 .
Conditioning regimen
The RIC protocol consisted of TBI 2 Â 4 Gy, fludarabine 4 Â 30 mg/m 2 , CY 120 (80) mg/kg and ATG rabbit (Fresenius) 40 mg/kg. The first 16 patients received 120 mg/kg of CY and the following 19 patients received 80 mg/kg of CY ( Table 2 ). The reduction was due to initially high TRM. The two patients transplanted at the Wiesbaden BMT unit received 120 mg/kg of CY and two or three times 2.5 mg/kg of ATG rabbit (Thymoglobulin, Merieux, Sangstat).
GvHD prophylaxis and stem cell source
GvHD prophylaxis consisted of cyclosporine A and a short course of methotrexate (15 mg/m 2 on day 1, 10 mg/m 2 on days 3 and 6). The initial cyclosporine dose was 5 mg/kg daily. Cyclosporine blood levels were aimed at 250-500 ng/ml. The stem cell source was bone marrow in 31 patients and peripheral blood in four patients.
Chimerism analysis
Chimerism of blood and bone marrow was analyzed using amplification of short tandem repeats (STRs) if donor and recipient had the same gender. For transplantation of male donor and female patient and vice versa, FISH analysis with hybridization probes for the X and Y chromosomes was performed (Vysis, Stuttgart, Germany).
Monitoring of minimal residual disease
For molecular monitoring post-BMT, we used a qualitative nested RT-PCR as published previously. 16 The sensitivity of this PCR approach was one BCR-ABL-positive cell in 10 6 normal cells (6 log). In addition, quantitative real-time RT-PCR using the LightCycler s system (Roche Diagnostics, Penzberg, Germany) was performed. The sensitivity of the real-time RT-PCR was one BCR-ABL-positive cell in 10 5 normal cells (5 log). The PCR protocol and the sequences of primers and hybridization probes have been published elsewhere. 17 
Definition of relapse
A relapse was defined as reappearance of Ph þ metaphases in bone marrow by cytogenetics, after engraftment with full donor chimerism. Relapse was defined as cytogenetic if it occurred without hematological or clinical signs of disease. Relapse was defined as hematological if hematologic or clinical signs of disease preceded or accompanied cytogenetic conformation.
Statistical analysis
Statistical analysis of the obtained data was performed using Pearson's w 2 test, Fisher's test, log-rank test and Kaplan-Meier analysis where appropriate. Data analysis was performed by using SPSS 11 for Windows software.
Results
Engraftment and chimerism
All RIC patients who survived longer than day þ 30 had a stable engraftment. The mean time from transplantation to neutrophil recovery (4500 Â 10 6 /l) was 20 days. One patient died of severe sepsis on day þ 20. This patient was just recovering from neutropenia (800 Â 10 6 /l leukocytes on day þ 26). Analyses of either blood or bone marrow chimerism were available in 26/35 patients post- BMT. All of these patients showed a 100% donor chimerism within 90 days post-BMT.
Acute and chronic GvHD
The incidence of acute GvHD II-IV was 48% (12 Â II and 5 Â III). A grade IV acute GvHD was not observed. The incidence of extensive chronic GvHD was 23% (8/35) ( Table 3) .
Transplant-related mortality
TRM at days þ 100 and þ 365 was 11 and 28.5% respectively. TRM of the 16 patients who had received CY 120 mg/kg was 18% at day þ 100 and 31% at day þ 365. The following 19 patients had received CY 80 mg/ kg. Here TRM at days þ 100 and þ 365 was 5 and 26% respectively (P ¼ 0.21), as shown in Figure 1 . However, reduction of CY to 80 mg/kg resulted in significantly less III-IV stomatitis (P ¼ 0.016) ( Table 3 ). A total of 11 patients died within the first year. Six patients died of infections and three patients died of GvHD. One patient died of acute cardiac failure 4 months after BMT. Another patient, who underwent transplantation without complications, died at home of unknown cause. Thus the leading cause of death within the first year was infection (55%) followed by GvHD (27%). Two patients died 3 years after BMT, one of pneumonia and other of myocardial infarction.
Minimal residual disease and relapse
All patients who survived longer than day þ 30 achieved a complete cytogenetic remission (CCR). Qualitative nested RT-PCR was performed for molecular monitoring of residual BCR-ABL fusion transcripts. Figure 2 Figure 2 Kaplan-Meier plots of TRM. TRM at day þ 100 was 18% in the CY 120 mg/kg group and 5% in the CY 80 mg/kg group (P ¼ 0.21). TRM after 1 year was 31% in the CY 120 mg/kg group and 26% in the CY 80 mg/kg group (P ¼ 0.68). In the other patient, response to therapy was short. BCR-ABL transcript levels increased once again. Thus, the dose of imatinib was escalated. However, this patient relapsed hematologically and is currently receiving DLI. The last patient has recently received the first dose of DLI and is too early for evaluation. The stage of the disease before transplantation significantly influenced the risk of relapse. Of the nine patients transplanted in second chronic or accelerated phase, 33% relapsed in contrast to 8% of the patients transplanted in first CP (P ¼ 0.048) (Figure 3 ).
Leukemia free and overall survival
After a median follow-up of 30 months (range 12-62), 22 of the 35 RIC patients (63%) are alive. The leukemia free survival (LFS) is 49% (Figure 4 ). Due to potent therapies for relapsing CML like imatinib and DLI, relapse did not have an influence on overall survival. The overall survival was 69% at 2 years and 59% at 5 years ( Figure 5) . No difference was observed between the CY 120 mg/kg and the CY 80 mg/kg group (P ¼ 0.91). The stage of disease (first CP or second CP/AP) also had no effect on overall survival (P ¼ 0.794). There was also no difference in the outcome for patients transplanted from a sibling or an unrelated donor (P ¼ 0.514). However, the time from diagnosis to transplantation had a significant impact on the overall survival. The probability of overall survival at 5 years of those patients transplanted within the first year from diagnosis was 79 vs 40% (P ¼ 0.049) ( Figure 6 ).
Discussion
RIC and nonmyeloablative stem cell transplantation (NST) are of growing interest in the field of allogeneic BMT. However, its use in CML has recently been discussed critically. Barrett and co-workers stated that NST may not be able to control CML sufficiently. 18 In the presented analysis, the conditioning intensity was reduced stepwise. The dose of TBI was reduced to 8 Gy and fludarabine was incorporated. This resulted in stable durable engraftment, complete donor chimerism and CCR. Due to the myeloablative character of our protocol, the duration of Probability of relapse (%) Figure 3 The probability of relapse was significantly higher in patients transplanted in second CP or AP as compared to first CP (P ¼ 0.048). Probability of overall survival (%) Figure 5 Kaplan-Meier plot of overall survival.
Dose-reduced conditioning in elderly CML patients M Weisser et al neutropenia was in the range of conventional allografting. A high prevalence of BCR-ABL-positive nested PCR was detected within the first 90 days post-BMT. However, this was not associated with increased cytogenetic relapse rates. After withdrawal of immunosuppression, the percentage of BCR-ABL-positive nested RT-PCR declined from 75 to 31% after 3 years. The incidence of cytogenetic relapse was 14%. This is comparable to the published relapse rates for CML after conventional BMT that range from 10 to 20% depending on the stage of the disease. 19, 20 Those patients transplanted in second or higher CP or AP had a significantly higher risk of cytogenetic relapse. Due to the availability of potent postrelapse therapies like DLI and imatinib, relapse did not have an impact on overall survival. TRM at days þ 100 and þ 365 was 11 and 28%, respectively. The reduction of CY from 120 to 80 mg/ kg showed a beneficial effect on short-term toxicity, resulting in significantly less severe stomatitis and a trend towards improved TRM þ 100.
The first year post-BMT seems to be crucial, as 10 patients died from transplant related causes within this first year. Infectious complications were the leading cause of death followed by GvHD. The probability of overall survival is 69% at 2 years and 59% at 5 years. According to the pretransplant risk score published by Gratwohl et al, 3 the overall survival of CML patients with a risk score of 3 or 4 lies between 52 and 60% after 1 year and between 50 and 55% after 2 years. Most importantly, those elderly CML patients transplanted within the first year had an overall survival of 79%, postulating that early allogeneic transplantation should be considered even in elderly patients.
Limited data on early-stage CML patients treated with RIC have been published thus far. Raiola et al 15 published a series of 15 CML patients in CP and AP, transplanted with thiotepa and CY conditioning. Relapse was detected in 27% of the patients. Another group transplanted 44 CML patients, including younger patients and blast crisis, with a reduced-intensity protocol using busulfan and fludarabine. Graft failure was seen in 10 patients. After a median follow-up of 562 days, 41% of the patients were alive and disease free. Of these patients, 52% had achieved a molecular remission. GvHD incidences were comparable to our patient cohort. 21 Niederwieser et al 22 recently published a study of 52 patients, including 11 mainly elderly, later stage CML, treated with NST. Graft failure occurred in two patients, relapse in two patients and another three patients suffered from disease progression. Eight CML patients died within the first year after allogeneic transplantation. Blum et al 23 transplanted 80 patients with reduced TBI dose (550 cGy). Of these, 22 patients had CML. The age ranged from 17-68 years and only HLA-identical sibling donors were included. They demonstrated stable engraftment and low transplant mortality, and in the good risk group low relapse and high overall survival of 80% were achieved. However, as the outcome of the CML patients was not evaluated separately and only sibling donors were included, the results are not completely comparable to our report. Blum et al observed an excessive amount of extensive chronic GvHD. This was probably due to the use of PBSC instead of BM as cell source. Prior studies have demonstrated improved survival in the PBSC group especially in later stage CML. PBSC was also associated with lower relapse rates and faster clearance of residual disease to the extent of higher risk of chronic GvHD. [24] [25] [26] Given the excellent results of conventional bone marrow transplantation in CP CML, 4 the potential benefit of PBSC in this setting remains questionable.
To our knowledge, our analysis comprises the largest homogeneous group of elderly CML patients transplanted with RIC. Our stepwise reduction of conditioning intensity provided stable engraftment and low relapse rates. Furthermore, our data demonstrate that excellent results can be achieved in elderly CML patients using RIC especially when allogeneic transplantation is performed in the early phase of the disease. In addition, further reduction of conditioning intensity is warranted.
Recently, the tyrosine kinase inhibitor imatinib (STI571) has been shown to induce major cytogenetic remissions in 87% of newly diagnosed patients. 27 Moreover, disease progression was lower than in a comparable group of patients treated with interferon a and cytosine arabinoside. The excellent results of imatinib in the induction of cytogenetic remission and prevention of disease progression have to be considered when consulting elderly patients for allogeneic transplantation. However, complete molecular remissions after imatinib treatment are rather rare events and therefore it remains questionable whether imatinib has the potential to cure the disease. Furthermore, in more advanced stages of CML, the development of resistance against imatinib has been observed frequently. 28 By contrast, the curative potential of allogeneic transplantation relies on an immune effect, which is likely to be sustained. The good results of transplantation in the first year after diagnosis may be due to a greater sensitivity of the CML cells or a smaller number of leukemic stem cells as targets. It is not known yet whether the treatment with imatinib changes the outcome of subsequent allogeneic Tx >1 year (N =16) Probability of overall survival (%) Figure 6 Patients transplanted within the first year from diagnosis had significantly higher overall survival (P ¼ 0.049).
Dose-reduced conditioning in elderly CML patients M Weisser et al transplantation. In advanced phases of disease, allogeneic transplantation following treatment with imatinib has been successful, if the disease responded to imatinib. Potentially, the induction of a state of minimal residual disease by imatinib allows a further dose reduction of the preparative regimen for allogeneic transplantation without compromising the cure rates in this elderly patient population.
